☆ 3.8 Letter

Comment on Drug survival analysis is not a good method for assessing the safety or effectiveness of systemic therapies in psoriasis

ACTAS DERMO-SIFILIOGRAFICAS (2017)

Get Full Text
Add to Collection

Journal

ACTAS DERMO-SIFILIOGRAFICAS
Volume 108, Issue 7, Pages 695-696

Publisher

ELSEVIER ESPANA S I
DOI: 10.1016/j.ad.2017.03.012

Keywords

-

Categories

Dermatology

Funding

  1. AbbVie
  2. Eli Lilly
  3. Pfizer
  4. Janssen
  5. MSD
  6. Novartis
  7. Lily
  8. Amgen
  9. Cellgene
  10. department of dermatology of Radboud university medical centre in Nijmegen in the Netherlands

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.